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Heart failure (HF) is associated with weight loss, and cachexia is a well-recognized
complication. Patients have an increased risk of osteoporosis and lose muscle bulk early in the
course of the disease. Basal metabolic rate is increased in HF, but general malnutrition may
play a part in the development of cachexia, particularly in an elderly population. There is
evidence for a possible role for micronutrient deficiency in HF. Selective deficiency of
selenium, calcium and thiamine can directly lead to the HF syndrome. Other nutrients,
particularly vitamins C and E and beta-carotene, are antioxidants and may have a protective
effect on the vasculature. Vitamins B6, B12 and folate all tend to reduce levels of
homocysteine, which is associated with increased oxidative stress. Carnitine, co-enzyme Q 10
and creatine supplementation have resulted in improved exercise capacity in patients with HF
in some studies. In this article, we review the relation between micronutrients and HF.
Chronic HF is characterized by high mortality and morbidity, and research effort has centered
on pharmacological management, with the successful introduction of angiotensin-converting
enzyme inhibitors and beta-adrenergic antagonists into routine practice. There is sufficient
evidence to support a large-scale trial of dietary micronutrient supplementation in HF. (J Am
Coll Cardiol 2001;37:1765–74) © 2001 by the American College of Cardiology
Heart failure (HF) affects approximately 10% of those over
80 years old (1). It is the leading cause of death in
industrialized countries (2) and the single most common
reason for medical admissions to hospitals (3). Recent
therapeutic advances have led to benefits with regard to
symptoms and prognosis (4). Nevertheless, a poor progno-
sis, persistently high readmission rates (5) and reduced
quality of life (6) remain features of the condition.
Much research effort has been expended on drug treat-
ments for chronic heart failure (CHF), but there has been
little attention paid to nonpharmacological management.
While it is generally considered that a high sodium diet may
be detrimental, little is known about other aspects of diet in
HF in terms of both general nutrition and micronutrients
such as vitamins and minerals. In this article, we will review
what is known about nutrition in HF, particularly as it
relates to micronutrients, and consider the potential thera-
peutic implications.
METHODS
A search strategy using Medline was used to identify all
articles published containing the key words “heart failure”
and its cognates and each of the micronutrients under
discussion. For this purpose, we defined a “micronutrient” as
an essential dietary component present in trace amount. For
each micronutrient, we considered the evidence from animal
experiments and the evidence that the nutrient may be
relevant to HF in man.
GENERAL NUTRITION
Cardiac cachexia was described by Hippocrates: “The flesh
is consumed and becomes water . . . the abdomen fills with
water; the feet and legs swell; the shoulders, clavicles, chest
and thigh melt away” (7). Weight loss or frank cachexia is
commonly seen (8), the prevalence increasing with worsen-
ing symptoms (9,10). Cachexia worsens the already poor
prognosis by a factor of 2.6 (9). More subtle loss of muscle
bulk occurs early in the disease (11).
There may be multiple etiologies to the weight loss (12).
Heart failure makes patients less active (13), which may
result in loss of muscle bulk, but the disease process itself
seems to contribute to the loss (14). Some HF patients
(15,16), but not all (17), have an increased resting metabolic
rate of up to 70% of daily energy expenditure, and this
proportion increases with symptomatic class (18).
There is a shift toward catabolism in HF (19). Catabolic
steroids are elevated (20), and there is an increase in
catabolic relative to anabolic steroids (21,22). There is also
insulin resistance (23,24) and resistance to the effects of
growth hormone (25). Tumor necrosis factor-alpha is raised
in HF (26), particularly in those with weight loss (21,27). It
may stimulate loss of appetite through downregulation of
the alpha3-adrenoceptors (28) and by the induction of leptin
expression in adipose tissue and reduction in body fat stores
(29).
Previous dietary studies in HF have been inconclusive but
have failed to take into account nutrient or caloric intake
(30) or have involved small numbers of patients (31).
Gastrointestinal malabsorption (possibly as a consequence
of gut edema) may be a cause of impaired nutrition. Fat
malabsorption particularly may affect elderly patients with
cardiac cachexia (32), which may, in turn, affect absorption
of fat-soluble vitamins.
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MINERALS
Deficiencies of specific micronutrients can cause HF. Pa-
tients with HF from other causes have a number of risk
factors for micronutrient deficiency. They are usually el-
derly, may have a poor general diet (33) and are prone to
excess urinary losses due to diuretic therapy.
Calcium and vitamin D. Calcium absorption is reduced in
people over 70 years of age because the gut may be less
sensitive to calcitriol and also because of lower renal syn-
thesis of calcitriol. Loop diuretics are calciuric (but thiazides
are not) (34). Older people make less vitamin D in the skin
after exposure to ultraviolet light (35).
There is a link between low calcium intake and higher
mortality from ischemic heart disease in postmenopausal
women (36). Hypocalcemia-induced cardiomyopathy in
humans, usually in young children with a congenital cause
for hypocalcemia, can respond dramatically to calcium
supplementation (37–39). Low calcium levels are potentially
proarrhythmic, being associated with QT prolongation (40)
and torsades de pointes (41), and hypocalcemic-associated
ventricular fibrillation has been reported (42).
Osteopenia or osteoporosis is seen in half the patients
with severe HF (43). Heart failure patients with cachexia
have lower calcium levels and lower bone mineral density
(44) than noncachectic patients and normal subjects.
Vitamin D is also important in the functioning of the
cardiovascular system. Rats fed on vitamin D-deficient
diets, but with calcium levels maintained by high-dose
calcium supplements, develop deteriorating myocardial con-
traction. Myocardial contraction returns to normal only
when vitamin D is supplemented (45). In another rat model,
vitamin D and retinoic acid reduced the hypertrophic
process induced by endothelin (46), which is raised in HF
(47).
Magnesium. Loop and thiazide diuretics increase magne-
sium loss. The incidence of magnesium deficiency in CHF
has been reported at more than 30% and is accompanied by
muscular magnesium deficiency (48), which may contribute
to symptoms of fatigue. Magnesium deficiency also causes a
positive sodium balance and negative potassium balance
(49).
Hypomagnesemia is associated with a worse prognosis in
HF (50,51) and an increase in the rate of ventricular ectopic
beats (50,51), both in the presence of left ventricular (LV)
dysfunction and normal cardiac function (52), and, in rats,
magnesium deficiency can increase the rate of adrenaline-
induced ventricular tachycardia (53). Magnesium replace-
ment results in a fall in the rate of ventricular arrhythmias
(54,55).
Deficiency of magnesium can lead to cardiac failure in
rats (56). This can be inhibited by sufficient quantities of
ascorbate (vitamin C), suggesting that free radical produc-
tion may be involved (57). Indeed the magnesium-
dependent isoform of adenylyl cyclase, an antioxidant en-
zyme, is reduced in rats with CHF (58). Heart failure as a
consequence of hypomagnesemia has also been observed in
humans, and correction of the magnesium levels leads to
improvement in (LV) function (59). Low magnesium status
is common in elderly patients with atrial fibrillation and HF
and can precipitate digoxin toxicity (60,61). Ventricular
arrhythmias in the context of idiopathic cardiomyopathy
may respond to magnesium therapy (62).
Zinc. Zinc deficiency is common in the elderly (63). Low
zinc levels correlate with intake of cardiovascular medication
and also with reduced nutritional protein (63). Low serum
(64,65) and high urinary zinc levels are found in HF (66),
possibly as a result of diuretic use.
Zinc deficiency is associated with higher levels of lipid
peroxides in rat hearts (67). Levels of lipid peroxidation are
markers of oxidative stress, suggesting that zinc acts as an
antioxidant (68). The combination of zinc deficiency and
ethanol can lead to contractile dysfunction in pre-ischemic
conditions in the rat model (69).
Manganese. Manganese is a constituent of the antioxidant
enzymes superoxide dismutase and adenylyl cyclase. Levels
of manganese are elevated in HF (64), and the expression of
the manganese isoform of adenylyl cyclase is not reduced in
rats with chronic LV dysfunction in contrast with the
magnesium-dependent isoform (58). However, mice lack-
ing the gene for manganese-superoxide dismutase die at 10
days of a dilated cardiomyopathy (70). Adriamycin—a
well-known cause of dilated cardiomyopathy—is associated
with lower myocardial levels of manganese-superoxide dis-
mutase (but not copper or zinc superoxide dismutase) and
glutathione peroxidase in rats (71).
Copper. Copper plays a role in the regulation of oxidative
free radicals, and deficiency increases the susceptibility of
lipoprotein peroxidation (72). Copper restriction leads to an
increased risk of myocyte oxidative damage (73) and may
lead to an increase in plasma cholesterol concentrations
(74,75).
Long-term copper restriction in rats can lead to myofi-
brillar disarray and mitochondrial fragmentation (76). Cy-
tochrome C oxidase activity is decreased in copper defi-
ciency (77), which could lead to mitochondrial impairment
and contribute to cardiac dysfunction. Copper-deficient
cardiomyopathy is a recognized entity (78), and the identi-
fication of the genetic basis for defects in the copper-
dependent ATP-ases have indicated a possible role of
copper deficiency in experimental and human cardiomyop-
athy (79).
Selenium. Selenium is a constituent of the antioxidant
enzyme glutathione peroxidase. Pure selenium deficiency is
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rare, but deficiency symptoms may occur when there is an
additional stress such as a vitamin E deficiency. An endemic
cardiomyopathy in China, Keshan disease, is a consequence
of selenium deficiency, which is also a risk factor for
peripartum cardiomyopathy (80). Selenium-deficient car-
diomyopathy has also been described in Western countries,
for example, in patients on long-term total parenteral
nutrition (81).
Ischemic heart disease and peripheral vascular disease
have been linked to low selenium levels (82). Selenium
deficiency leads to increased levels of lipid peroxidation and,
thereby, an increase in oxidative stress. Selenium may
protect tissues from oxidative damage, preserve cells’ ability
to produce ubiquinone and also reduce its breakdown by
oxidative degeneration (83). Deficiency leads to mitochon-
drial ultrastructural changes such as loss of cristae (84).
In pig models of myocardial infarction, selenium reduced
the occurrence of late ventricular potentials in the border
zone (82). A selenium-based antihypertensive agent (85),
which may work by the smooth muscle relaxant properties
of the metal, is under development.
VITAMINS
Vitamin A. There is epidemiological evidence associating
low beta-carotene intake and the risk of acute myocardial
infarction (AMI) (86). It has, in combination with vitamin
E and selenium, been shown to reduce overall cardiovascular
mortality in a low-risk population (87), but, alone, it may
reduce cardiac events (88). There is little clear evidence
supporting its routine supplementation in patients with HF
(89), and there are no published data on levels in CHF.
Thiamine (B1). Thiamine (B1) is a coenzyme for decar-
boxylation in carbohydrate metabolism. Deficiency leads to
impaired oxidative metabolism through inhibition of the
citric acid cycle and the hexose monophosphate shunt.
Thiamine deficiency can induce high-output cardiac failure
due to the accumulation of pyruvate and lactate, leading to
intense vasodilation. Response to thiamine is brisk and
often with full recovery.
In rats, myocyte contraction is reduced during thiamine
deficiency (90). Frusemide-induced thiamine deficiency was
first described in rats (91), and thiamine uptake by cardiac
myocytes is significantly impaired both by digoxin and
frusemide, the drugs having an additive effect if given
together (92). Low whole blood thiamine levels have been
documented in patients with CHF on loop diuretics (93,94)
and hospitalized elderly patients (95,96).
Thiamine supplementation in patients with moderate-to-
severe CHF taking 80 mg of frusemide induced a significant
improvement in LV ejection fraction and symptoms (97)
and a rise in blood pressure of 10 mm Hg (93).
Riboflavin (B2). Rats fed on a riboflavin-deficient diet
have abnormal lipid metabolism, with a reduction in the
beta-oxidation of fatty acids. It is not known whether
riboflavin deficiency has any detrimental effect on cardiac
functioning. Children with CHF due to congenital heart
disease have an increased risk of riboflavin deficiency (98).
Niacin and pantothenic acid. There is no evidence con-
necting these nutrients to heart disease.
Vitamin B6. Low pyridoxal-59-phosphate is a risk factor
for coronary artery disease and extracranial carotid artery
disease mediated, in part, by elevated homocysteine levels
(99–101). However, low B6 levels are an independent risk
factor for coronary artery disease even when homocysteine is
taken into account (102). There are no reports of pyridoxal-
59-phosphate levels in HF.
Folate. Folate is required for the conversion of homocys-
teine to methionine, and a strong inverse relationship exists
between folate consumption and homocysteine levels
among patients with and without hyperhomocysteinemia
(103,104).
Tissue levels of vitamins B12, B6 and folate are not closely
related to blood levels, and many more elderly patients may
be deficient than are recognized (105). There is epidemio-
logical evidence of an inverse link between folate consump-
tion and risk of coronary heart disease (106,107).
Vitamin B12. Vitamin B12 deficiency is associated with
elevated homocysteine and, thereby, an elevated risk for
coronary artery disease (99,100), but no published work has
looked at B12 status in patients with heart disease.
Vitamin C. A 20-year follow-up study suggested that
higher levels of intake of vitamin C correlated closely with
a reduced risk of death from stroke, and this association was
as strongly related with death as diastolic blood pressure
(108). There was however, no relation between vitamin C
intake and deaths from heart disease, a finding replicated
elsewhere (109). In contrast, a study from Finland on
middle-aged men showed an increased risk of death from
coronary heart disease over eight years of follow-up in those
with low plasma ascorbate concentration (110).
The oxidation of low-density lipoprotein has been pro-
posed to be one of the initiating features in the process of
atherosclerosis. In a hamster model, pretreatment with
vitamin C before oxidized low-density lipoprotein exposure
prevented leukocyte adhesion to the endothelium as well as
the formation of leukocyte-platelet aggregates (111).
Hypertensive patients have an attenuated vasodilatory
response to acetylcholine, which is partially reversed by
vitamin C (112), and ascorbic acid supplementation can
significantly lower blood pressure in hypertensive patients
(113). Vitamin C improves endothelial function in diabetics
(114,115) and smokers (116) when infused intra-arterially
(cigarette smokers have lower plasma and leukocyte levels of
vitamin C [117]). Hypercholesterolemic endothelial dys-
function (118) (possibly due to oxidative stress) is improved
by vitamin C infusions (119). Thirty days of oral treatment
with vitamin C improves endothelium-dependent vasodila-
tion in patients with coronary artery disease (120), and even
a single dose of 2 g can improve vasomotor function after
2 h (121).
Whether vitamin C levels are reduced in HF is unknown,
1767JACC Vol. 37, No. 7, 2001 Witte et al.
June 1, 2001:1765–74 Micronutrients in HF
but there is evidence that the elderly are deficient (33).
Improvements of endothelial dysfunction in HF have been
seen with vitamin C (122).
Vitamin E. High vitamin E intake is associated with a
lower incidence of coronary heart disease in middle-aged
subjects (123). The men in the top 20% of vitamin intake
had a 40% lower risk of developing coronary artery disease
(124), and, in women, a 34% risk reduction was seen (125).
Similar results are seen in those 65 years old and older with
additional benefits if subjects took both vitamin E and
vitamin C supplements (126).
Vitamin E in healthy volunteers led to a reduction of
platelet stickiness (127,128), an effect that has also been
seen in diabetics and heart transplant recipients (129,130).
Vitamin E inhibits platelet protein kinase C stimulation at
physiological concentrations (131,132), which gives alpha-
tocopherol the ability to control smooth muscle cell prolif-
eration (133). In healthy adults, pretreatment with 800 IU
of vitamin E and 1 g of vitamin C leads to normalization of
the responsiveness of the vascular endothelium after a
high-fat meal (134), and the endothelial function of
cholesterol-fed rabbits improves with low-dose alpha-
tocopherol (135).
Vitamin E leads to reduced surface expression of adhe-
sion molecules on leukocytes and endothelial cells (136),
resulting in reduced leukocyte-endothelium cell interac-
tions.
In a pig model of acute infarction, high dose vitamin E
combined with intravenous vitamin C, led to significantly
less myocardial damage (137). This finding suggests that
vitamin C aids the antioxidant action of vitamin E, and it
may be able to regenerate formed vitamin E radicals at the
border of the lipid and aqueous phase in cell membranes
(138).
Despite these theoretical reasons for benefit from vitamin
E, there are few clear data to suggest that it benefits patients
with ischemic heart disease (139,140). Vitamin E reduces
indexes of oxidative stress in HF patients (141). The use of
vitamin E after AMI has been advocated by some, but it is
far from being established therapy (142,143). The Heart
Outcomes Prevention Evaluation (HOPE) study did not
show any benefit for vitamin E treated patients at high risk
of coronary disease (144), and a large multicenter postin-
farction trial also showed no benefit from using vitamin E
(145).
Ubiquinone (co-enzyme Q 10). Co-enzyme Q 10 is an
endogenous vitamin-like, fat-soluble quinone found in high
concentrations in the mitochondria of myocardium, liver
and kidney. It is an electron carrier in the mitochondrial
synthesis of ATP, has membrane stabilizing properties and
is a powerful antioxidant.
Patients with HF have lower levels of myocardial coen-
zyme Q 10 compared with controls (146,147). Low plasma
coenzyme Q 10 levels are associated with an increased
mortality in HF (148), but there is disagreement on the
benefits of ubiquinone in patients with CHF. Uncontrolled
studies have shown beneficial effects on ejection fraction,
exercise tolerance and New York Heart Association status at
Figure 1. Homocysteine metabolism. Homocysteine metabolism is dependent upon folate and vitamins B6 and B12, and deficiencies of any of these may
result in an increase in homocysteine.
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a variety of doses (149–151). Some placebo-controlled trials
(152,153) have given similar results and also show a reduc-
tion in hospitalizations (153), but other randomized con-
trolled trials have shown no benefit from coenzyme Q 10
therapy (154–156).
The production of ubiqinone is reduced by hydroxy-
methylglutaryl coenzyme A reductase inhibitor (statin)
therapy (157,158). There is overwhelming evidence of the
benefit of statins for the secondary prevention of coronary
heart disease, but patients with HF have been specifically
excluded from statin trials. It may be that the effect of
reducing ubiquinone in such patients is deleterious.
HOMOCYSTEINE AND HEART DISEASE
Several of the vitamins described interact through the
metabolism of homocysteine (Fig. 1). Hyperhomocysteine-
mia is a potent risk factor for cardiovascular disease
(159,160). Levels of only 12% above the upper limit of
normal are associated with a threefold increase in risk of
AMI (160). Levels rise with age, which may be a reflection
of particularly poor intake of vitamins B12 and B6 and folate
in the elderly population (161). Homocysteine is also
important independently of these vitamins (162).
A hyperhomocysteinemic state could promote atheroscle-
rosis by:
1) alteration of platelet function and coagulation factors
(163–165),
2) endothelial damage and dysfunction (166,167),
3) encouraging the oxidation of low-density lipoprotein
(168,169),
4) smooth muscle proliferation (170,171), and
5) endothelial-leukocyte interactions (172).
Homocysteine-lowering treatment with folic acid and vita-
min B6 is possible (173), and, in the siblings of patients with
premature atherosclerotic disease, this therapy is associated
with a decreased occurrence of abnormal exercise tests
(174).
OTHER NUTRITIONAL SUPPLEMENTS
Carnitine. Carnitine supplementation is thought to im-
prove the utilization of pyruvate in the Kreb’s cycle (175)
and, thereby, improve muscle metabolism. It has been
investigated in patients undergoing cardiac surgery (176)
and in patients with angina pectoris (177–179), AMI
(180,181), shock (182) and peripheral vascular disease
(183). There was some improvement on exercise tolerance
in patients with limiting ischemic symptoms, but there
remains a lack of strong evidence for the use of carnitine in
any of these situations. Oral propionyl-L-carnitine has, in
some studies (175) but not all (184), shown improved
Table 1. The Potential Contribution of Micronutrient Deficiency to the Heart Failure Syndrome
Micronutrient Deficiency State Relevance of Deficiency to HF Effects of Supplementation
Thiamine Beri beri Specific cardiomyopathy and frusemide-induced
thiamine deficiency (93)
Improvements in hemodynamics (93,97)
Riboflavin Increased prevalence in children with
chronic heart failure (98)
None
Magnesium Arrhythmias Arrythmogenic (51); can worsen
heart failure (56,59)
Reduced arrhythmias (54), improvement in
cardiac function with replacement (59)
Calcium/vitamin D Osteoporosis Osteoporosis common (43); hypocalemia-induced
cardiomyopathy (38)
Improvements in cardiomyopathy (38),
reduced effects of endothelin
Zinc Common in those with heart failure (66);
contractile dysfunction in combination with
ethanol (69)
Not known
Copper Myocyte damage (73), myofibrillar disarray (76),
copper deficient cardiomyopathy (78)
Not known
Selenium Selenium deficient cardiomyopathy (81) Not known
Vitamin A Loss of antioxidant properties Not known
Niacin Pellagra Unknown Not known




Folate Macrocytic anemia Common in the elderly (105);
homocysteine levels raised (103)
Not known
Vitamin B12 Pernicious anemia Homocysteine levels raised Not known
Vitamin C Scurvy Loss of antioxidant Improves endothelial function
(114–116,119), acts as antioxidant (111)
Vitamin E Reduced platelet aggregation (128);
inhibition of smooth muscle proliferation (132)
Reduced oxidative stress in HF (141)
Ubiquinone Low in heart failure patients (146);
associated with increased mortality (148)
Improved ejection fraction, exercise
tolerance, symptoms (149–151)
The final column summarizes the evidence in favor of dietary supplementation in HF.
HF 5 heart failure.
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exercise tolerance (but not hemodynamic variables) in pa-
tients with CHF.
Creatine phosphate. Creatine is used to improve athletic
performance. Patients with CHF develop a skeletal myop-
athy (185). Muscle contraction and relaxation is fuelled
through the dephosphorylation of ATP, which must be
rapidly resynthesized. Creatine serves as a phosphate donor
to maintain high levels of intracellular ATP, and creatine
supplementation increases the rate of phosphocreatine re-
synthesis (186). Skeletal muscle strength and endurance are
improved in patients with CHF after short-term oral
creatine supplementation, but there is no effect on cardiac
contractility (187). Creatine administered intravenously im-
proves ejection fraction (188). The improvements in skeletal
muscle function are predominantly seen in patients with low
levels of creatine and phosphocreatine in their skeletal
muscles (187), and this is not a ubiquitous finding in
patients with CHF (187,189).
It is possible that creatine is of benefit in some CHF
patients, but long-term safety issues have yet to be ad-
dressed; the improvements have not been shown to be
sustained, and the patient group most likely to benefit can
currently be identified only by muscle biopsy.
SUMMARY
Deficiency of many micronutrients and vitamins is associ-
ated with the development of HF or may contribute to
cardiovascular disease (Table 1). Patients with CHF may
become deficient in micronutrients due to reduced intake,
excessive consumption in some instances and increased loss
induced by diuretic therapy. In addition, HF is associated
with general loss of body tissue. It is possible that modern
treatment of HF and an improved quality of life reduces the
incidence of nutritional deficiency. The effects of protein-
energy dietary support in HF are not known. Studies of
supplementation of some individual micronutrients have
shown improved exercise tolerance and reduced symptoms.
Micronutrient supplementation is a potentially simple
treatment, and the effects need to be tested in a randomized,
placebo-controlled trial in patients already receiving optimal
medical therapy. Two alternative approaches are to conduct
a single trial with multiple nutrients or multiple trials
looking at each nutrient in turn. The former strategy would
at least give an answer over a relatively short period, and
further investigation could be aimed at identifying a partic-
ular factor if the trial was positive.
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